Innovation Spirits
We have independently developed 10 minimally invasive interventional treatment solutions targeting tricuspid valve diseases, mitral valve diseases, aortic valve diseases, and heart failure. All products are based on our original innovation and possess global patents and independent intellectual property rights.

MicroFlux is our proprietary first-generation transcatheter device for the treatment of HFpEF. It works by creating a small opening in the atrial septum, and once MicroFlux is deployed, it forms a passage between the left and the right atrium that enables the left atrium to decompress at rest and physical activity, with the aim of lowering left atrial pressure.